ADORA2A and Parkinson disease: An A2A adenosine receptor (A2AR) prodrug antagonist was also administered in this model as several A2AR antagonists are undergoing clinical trials to assess their capacity to alleviate the motor symptoms of PD and/or to prevent levodopa-induced involuntary movements.